CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66,726 enrolled
Drug / intervention
insulin aspart +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00869908
NCT00869908N/ACompleted
CompareCT.gov

The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study

Novo Nordisk A/S·observational·Posted Mar 26, 2009·Updated Jan 19, 2017

In Brief

An observational study evaluating insulin aspart, insulin detemir, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 66,726 participants across 22 sites in 22 countries.

Detailed Summary

This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice. After the physician's decision to start insulin treatment using NovoMix® 30, Levemir® or NovoRapid® (alone or combined), type 2 diabetics will be eligible to be included in this study at the physician's discretion

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAlgeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Jordan, Libya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russia, Saudi Arabia, Singapore, South Korea, Taiwan, Tunisia, Turkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 26, 2009
Enrollment StartNov 1, 2008
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.3 years ago

Interventions

insulin aspartdrug

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

insulin detemirdrug

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

biphasic insulin aspartdrug

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation